Home Newsfeeds Cocrystal Pharma Q2 EPS $(0.25) Down From $(0.04) YoY

Cocrystal Pharma Q2 EPS $(0.25) Down From $(0.04) YoY

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.25) per share. This is a 525 percent decrease over losses of $(0.04) per share from the same period last year.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.25) per share. This is a 525 percent decrease over losses of $(0.04) per share from the same period last year.

World Acceptance To Gain From Lower Credit Provisions In FY24, Analyst Raises Estimates

By Nabaparna Bhattacharya

July 24, 3:20 PM

BMO Capital Markets analyst James Fotheringham reiterated an Underperform rating on World Acceptance Corporation (NASDAQ: WRLD),

WRLD

Needham Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $60

By Benzinga Newsdesk

November 4, 6:40 AM

Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $62 to $60.

RCKT

Flat Footed LLC Issues Statement Regarding Growing Shareholder Opposition To Diversified Healthcare Trust’s Proposed Merger With Office Properties Income Trust

By Happy Mohamed

July 19, 8:10 AM

Offers to Meet with Leadership to Discuss Superior Alternatives to the Value-Destructive Deal Believes DHC and OPI's Recent Fear-Mongering and Delay Tactics are Desperate Attempts to Salvage the Deal Following

DHC

Biden Joining Trump’s Truth Social Platform To Go ‘Into The Lion’s Den’ To Point Out Hypocrisy Of Republicans, Share His Truth, Have Fun

By Chris Katje

October 16, 5:25 PM

Former President Donald Trump launched Truth Social as his social platform of choice after previously being banned from several leading platforms, including Twitter (now X), Facebook and Instagram, as related to the events of the Jan.

DWAC

Cocrystal Pharma Q2 EPS $(0.25) Down From $(0.04) YoY

Related Posts

World Acceptance To Gain From Lower Credit Provisions In FY24, Analyst Raises Estimates

Needham Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $60

Flat Footed LLC Issues Statement Regarding Growing Shareholder Opposition To Diversified Healthcare Trust’s Proposed Merger With Office Properties Income Trust

Biden Joining Trump’s Truth Social Platform To Go ‘Into The Lion’s Den’ To Point Out Hypocrisy Of Republicans, Share His Truth, Have Fun